High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients
© 2021 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology..
Severe acute respiratory syndrome coronavirus 2 is responsible for coronavirus disease 2019 (COVID-19). While COVID-19 is often benign, a subset of patients develops severe multilobar pneumonia that can progress to an acute respiratory distress syndrome. There is no cure for severe COVID-19 and few treatments significantly improved clinical outcome. Dexamethasone and possibly aspirin, which directly/indirectly target the biosynthesis/effects of numerous lipid mediators are among those options. Our objective was to define if severe COVID-19 patients were characterized by increased bioactive lipids modulating lung inflammation. A targeted lipidomic analysis of bronchoalveolar lavages (BALs) by tandem mass spectrometry was done on 25 healthy controls and 33 COVID-19 patients requiring mechanical ventilation. BALs from severe COVID-19 patients were characterized by increased fatty acids and inflammatory lipid mediators. There was a predominance of thromboxane and prostaglandins. Leukotrienes were also increased, notably LTB4 , LTE4 , and eoxin E4 . Monohydroxylated 15-lipoxygenase metabolites derived from linoleate, arachidonate, eicosapentaenoate, and docosahexaenoate were also increased. Finally yet importantly, specialized pro-resolving mediators, notably lipoxin A4 and the D-series resolvins, were also increased, underscoring that the lipid mediator storm occurring in severe COVID-19 involves pro- and anti-inflammatory lipids. Our data unmask the lipid mediator storm occurring in the lungs of patients afflicted with severe COVID-19. We discuss which clinically available drugs could be helpful at modulating the lipidome we observed in the hope of minimizing the deleterious effects of pro-inflammatory lipids and enhancing the effects of anti-inflammatory and/or pro-resolving lipid mediators.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 35(2021), 6 vom: 25. Juni, Seite e21666 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Archambault, Anne-Sophie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.05.2021 Date Revised 17.06.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1096/fj.202100540R |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325823006 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325823006 | ||
| 003 | DE-627 | ||
| 005 | 20231225193248.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1096/fj.202100540R |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1086.xml |
| 035 | |a (DE-627)NLM325823006 | ||
| 035 | |a (NLM)34033145 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Archambault, Anne-Sophie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.05.2021 | ||
| 500 | |a Date Revised 17.06.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology. | ||
| 520 | |a Severe acute respiratory syndrome coronavirus 2 is responsible for coronavirus disease 2019 (COVID-19). While COVID-19 is often benign, a subset of patients develops severe multilobar pneumonia that can progress to an acute respiratory distress syndrome. There is no cure for severe COVID-19 and few treatments significantly improved clinical outcome. Dexamethasone and possibly aspirin, which directly/indirectly target the biosynthesis/effects of numerous lipid mediators are among those options. Our objective was to define if severe COVID-19 patients were characterized by increased bioactive lipids modulating lung inflammation. A targeted lipidomic analysis of bronchoalveolar lavages (BALs) by tandem mass spectrometry was done on 25 healthy controls and 33 COVID-19 patients requiring mechanical ventilation. BALs from severe COVID-19 patients were characterized by increased fatty acids and inflammatory lipid mediators. There was a predominance of thromboxane and prostaglandins. Leukotrienes were also increased, notably LTB4 , LTE4 , and eoxin E4 . Monohydroxylated 15-lipoxygenase metabolites derived from linoleate, arachidonate, eicosapentaenoate, and docosahexaenoate were also increased. Finally yet importantly, specialized pro-resolving mediators, notably lipoxin A4 and the D-series resolvins, were also increased, underscoring that the lipid mediator storm occurring in severe COVID-19 involves pro- and anti-inflammatory lipids. Our data unmask the lipid mediator storm occurring in the lungs of patients afflicted with severe COVID-19. We discuss which clinically available drugs could be helpful at modulating the lipidome we observed in the hope of minimizing the deleterious effects of pro-inflammatory lipids and enhancing the effects of anti-inflammatory and/or pro-resolving lipid mediators | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a docosanoids | |
| 650 | 4 | |a eicosanoids | |
| 650 | 4 | |a eoxins | |
| 650 | 4 | |a specialized pro-resolving mediators | |
| 650 | 4 | |a thromboxane | |
| 650 | 7 | |a 14-cysteinyl-15-hydroxy-5,8,10,12-eicosatetraenoic acid |2 NLM | |
| 650 | 7 | |a Lipoxins |2 NLM | |
| 650 | 7 | |a lipoxin A4 |2 NLM | |
| 650 | 7 | |a Leukotriene B4 |2 NLM | |
| 650 | 7 | |a 1HGW4DR56D |2 NLM | |
| 650 | 7 | |a Leukotriene E4 |2 NLM | |
| 650 | 7 | |a 75715-89-8 |2 NLM | |
| 700 | 1 | |a Zaid, Younes |e verfasserin |4 aut | |
| 700 | 1 | |a Rakotoarivelo, Volatiana |e verfasserin |4 aut | |
| 700 | 1 | |a Turcotte, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Doré, Étienne |e verfasserin |4 aut | |
| 700 | 1 | |a Dubuc, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Cyril |e verfasserin |4 aut | |
| 700 | 1 | |a Flamand, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Amar, Youssef |e verfasserin |4 aut | |
| 700 | 1 | |a Cheikh, Amine |e verfasserin |4 aut | |
| 700 | 1 | |a Fares, Hakima |e verfasserin |4 aut | |
| 700 | 1 | |a El Hassani, Amine |e verfasserin |4 aut | |
| 700 | 1 | |a Tijani, Youssef |e verfasserin |4 aut | |
| 700 | 1 | |a Côté, Andréanne |e verfasserin |4 aut | |
| 700 | 1 | |a Laviolette, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Boilard, Éric |e verfasserin |4 aut | |
| 700 | 1 | |a Flamand, Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Flamand, Nicolas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t FASEB journal : official publication of the Federation of American Societies for Experimental Biology |d 1989 |g 35(2021), 6 vom: 25. Juni, Seite e21666 |w (DE-627)NLM01261730X |x 1530-6860 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2021 |g number:6 |g day:25 |g month:06 |g pages:e21666 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1096/fj.202100540R |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2021 |e 6 |b 25 |c 06 |h e21666 | ||